Targeted cancer therapy: conferring specificity to cytotoxic drugs.

By R. Chari. Accounts of Chemical Research, 2008

781 citations recorded by the source corpus.

Subfields: Organic Chemistry, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/e2652ccce683be6194269d775f85df984a7d2845

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Organic Chemistry

1. Paul Polakis
2. S. Bhakta
3. S. Panowski
4. Jagath R Junutula
5. H. Raab

In Radiology, Nuclear Medicine and Imaging

1. M. Sliwkowski
2. Paul Polakis
3. S. Bhakta
4. S. Panowski
5. Jagath R Junutula
6. H. Raab
7. M. Lacouture

Citations in the corpus

• Site-specific antibody drug conjugates for cancer therapy (2013, methodology): “An immune response mounted against an ADC, such as human anti-mouse antibodies (HAMA) against a murine ADC, can prevent repeat cycles of therapy.(23) It is also important to select an antibody with optimal PK properties (longer half-life with slower clearance in plasma).”
• Antibody Drug Conjugates for Cancer Therapy (2016, background): “the hydrophobic nature of maytansinoids and auristatins can drive antibody aggregation and negatively impact pharmacokinetics (Hamblett et al., 2004; Chari, 2008).”
• Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates (2012, background): “and by selecting the appropriate antibody and payloa”